Daryl Tan-Yeung Lau, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B, Chronic | 31 | 2023 | 393 | 5.910 |
Why?
|
| Hepatitis B virus | 32 | 2023 | 513 | 4.270 |
Why?
|
| Hepatitis B | 14 | 2023 | 695 | 2.940 |
Why?
|
| Hepatitis B Surface Antigens | 12 | 2023 | 305 | 2.360 |
Why?
|
| Hepatitis B e Antigens | 15 | 2023 | 133 | 2.140 |
Why?
|
| Hepatitis B Core Antigens | 6 | 2023 | 92 | 1.480 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2022 | 2214 | 1.310 |
Why?
|
| Antiviral Agents | 29 | 2023 | 2987 | 1.290 |
Why?
|
| Hepatitis C, Chronic | 9 | 2022 | 1031 | 1.170 |
Why?
|
| DNA, Viral | 19 | 2023 | 2225 | 1.130 |
Why?
|
| Liver Neoplasms | 10 | 2022 | 4253 | 1.030 |
Why?
|
| Hepatitis B Antibodies | 3 | 2022 | 159 | 0.840 |
Why?
|
| Cryoglobulinemia | 1 | 2022 | 87 | 0.810 |
Why?
|
| Hepatitis C | 7 | 2022 | 1591 | 0.770 |
Why?
|
| Hepacivirus | 11 | 2022 | 1379 | 0.700 |
Why?
|
| Virus Activation | 2 | 2018 | 319 | 0.680 |
Why?
|
| Interferon-alpha | 6 | 2014 | 895 | 0.670 |
Why?
|
| Liver Cirrhosis | 9 | 2022 | 1863 | 0.630 |
Why?
|
| Superinfection | 1 | 2018 | 65 | 0.630 |
Why?
|
| Hepatitis E | 1 | 2018 | 76 | 0.590 |
Why?
|
| Alanine Transaminase | 10 | 2021 | 592 | 0.580 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2022 | 685 | 0.560 |
Why?
|
| Kupffer Cells | 2 | 2013 | 142 | 0.530 |
Why?
|
| Liver | 10 | 2020 | 7474 | 0.530 |
Why?
|
| RNA, Viral | 4 | 2021 | 2902 | 0.380 |
Why?
|
| Interferons | 5 | 2019 | 706 | 0.370 |
Why?
|
| Interferon Regulatory Factor-3 | 2 | 2008 | 123 | 0.360 |
Why?
|
| Aspartate Aminotransferases | 4 | 2015 | 418 | 0.280 |
Why?
|
| Hepatitis A Antibodies | 1 | 2005 | 18 | 0.270 |
Why?
|
| Viral Load | 7 | 2019 | 3299 | 0.250 |
Why?
|
| Immune Tolerance | 1 | 2012 | 2258 | 0.230 |
Why?
|
| Platelet Count | 3 | 2015 | 781 | 0.230 |
Why?
|
| Genotype | 8 | 2021 | 12951 | 0.230 |
Why?
|
| North America | 3 | 2021 | 1249 | 0.220 |
Why?
|
| Immunity, Innate | 2 | 2012 | 2958 | 0.220 |
Why?
|
| Cryoglobulins | 1 | 2022 | 59 | 0.210 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2009 | 241 | 0.210 |
Why?
|
| Antigens, Surface | 2 | 2023 | 1663 | 0.200 |
Why?
|
| alpha-Fetoproteins | 1 | 2022 | 224 | 0.200 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2020 | 30 | 0.190 |
Why?
|
| Biopsy | 7 | 2020 | 6756 | 0.180 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1799 | 0.180 |
Why?
|
| Humans | 63 | 2023 | 744343 | 0.180 |
Why?
|
| Adenine | 1 | 2004 | 936 | 0.170 |
Why?
|
| Liver Function Tests | 3 | 2019 | 528 | 0.170 |
Why?
|
| Polyethylene Glycols | 3 | 2022 | 1182 | 0.170 |
Why?
|
| Adult | 32 | 2023 | 214055 | 0.160 |
Why?
|
| Liver Diseases | 2 | 2013 | 1253 | 0.160 |
Why?
|
| Virus Replication | 6 | 2022 | 2534 | 0.160 |
Why?
|
| Hepatitis B Vaccines | 1 | 2019 | 194 | 0.150 |
Why?
|
| Actins | 1 | 2005 | 2121 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2019 | 342 | 0.150 |
Why?
|
| Liver Failure, Acute | 1 | 2018 | 165 | 0.150 |
Why?
|
| Female | 35 | 2022 | 380194 | 0.140 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 5524 | 0.140 |
Why?
|
| Viremia | 1 | 2019 | 736 | 0.140 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 12072 | 0.140 |
Why?
|
| Genetic Variation | 4 | 2021 | 6544 | 0.130 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 3086 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2018 | 2026 | 0.130 |
Why?
|
| Lamivudine | 3 | 2007 | 342 | 0.130 |
Why?
|
| Guanine | 1 | 2016 | 274 | 0.130 |
Why?
|
| Fatigue | 1 | 2022 | 1531 | 0.130 |
Why?
|
| Electricity | 1 | 2015 | 182 | 0.120 |
Why?
|
| Microtechnology | 1 | 2014 | 70 | 0.120 |
Why?
|
| Hepatitis B Antigens | 1 | 2013 | 40 | 0.120 |
Why?
|
| Gastroenterology | 1 | 2020 | 536 | 0.120 |
Why?
|
| Puerperal Disorders | 1 | 2016 | 275 | 0.120 |
Why?
|
| Hepatocytes | 2 | 2012 | 1211 | 0.120 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2015 | 214 | 0.110 |
Why?
|
| STAT Transcription Factors | 1 | 2014 | 182 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 10180 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 9438 | 0.110 |
Why?
|
| Middle Aged | 22 | 2021 | 213383 | 0.110 |
Why?
|
| Janus Kinases | 1 | 2014 | 244 | 0.110 |
Why?
|
| Male | 29 | 2022 | 350118 | 0.110 |
Why?
|
| Host-Pathogen Interactions | 2 | 2018 | 1477 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2019 | 1320 | 0.100 |
Why?
|
| Recombinant Proteins | 4 | 2014 | 6622 | 0.100 |
Why?
|
| Lectins | 1 | 2013 | 513 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 270 | 0.100 |
Why?
|
| Nanostructures | 1 | 2015 | 551 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2015 | 499 | 0.090 |
Why?
|
| Hepatitis C Antigens | 1 | 2009 | 34 | 0.090 |
Why?
|
| Age Factors | 3 | 2022 | 18370 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 4803 | 0.090 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 927 | 0.090 |
Why?
|
| Algorithms | 4 | 2021 | 13881 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 13989 | 0.090 |
Why?
|
| Receptors, Virus | 1 | 2012 | 648 | 0.080 |
Why?
|
| Viral Core Proteins | 1 | 2009 | 162 | 0.080 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 668 | 0.080 |
Why?
|
| Interferon Type I | 1 | 2012 | 542 | 0.080 |
Why?
|
| Nanotechnology | 1 | 2014 | 710 | 0.080 |
Why?
|
| Serologic Tests | 2 | 2022 | 374 | 0.080 |
Why?
|
| Inflammasomes | 1 | 2013 | 495 | 0.080 |
Why?
|
| Young Adult | 7 | 2021 | 56430 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 11366 | 0.080 |
Why?
|
| RNA | 3 | 2023 | 2749 | 0.080 |
Why?
|
| Quantum Dots | 1 | 2009 | 172 | 0.080 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 522 | 0.080 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2009 | 271 | 0.080 |
Why?
|
| Mass Screening | 1 | 2003 | 5255 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 972 | 0.070 |
Why?
|
| Hepatitis, Chronic | 1 | 2006 | 52 | 0.070 |
Why?
|
| Hepatitis A virus | 1 | 2005 | 15 | 0.070 |
Why?
|
| Drug Resistance, Viral | 2 | 2011 | 820 | 0.070 |
Why?
|
| Aged | 9 | 2021 | 163280 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2021 | 53288 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 39050 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2004 | 615 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 57776 | 0.060 |
Why?
|
| Chromatography | 1 | 2003 | 206 | 0.060 |
Why?
|
| Incidence | 4 | 2022 | 20947 | 0.060 |
Why?
|
| Models, Theoretical | 2 | 2012 | 3589 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2015 | 19229 | 0.060 |
Why?
|
| DNA, Circular | 1 | 2022 | 97 | 0.050 |
Why?
|
| Pregnancy | 3 | 2019 | 29144 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2008 | 727 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 623 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 4560 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 1912 | 0.050 |
Why?
|
| United States | 8 | 2021 | 69872 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 41006 | 0.050 |
Why?
|
| Canada | 2 | 2019 | 2065 | 0.050 |
Why?
|
| Adolescent | 5 | 2021 | 85781 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 3870 | 0.050 |
Why?
|
| ROC Curve | 3 | 2020 | 3527 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2013 | 2303 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 383 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2013 | 5021 | 0.040 |
Why?
|
| Phenotype | 4 | 2019 | 16365 | 0.040 |
Why?
|
| Cohort Studies | 5 | 2023 | 40561 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2018 | 77449 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 14722 | 0.040 |
Why?
|
| Child | 3 | 2022 | 77709 | 0.040 |
Why?
|
| Population Groups | 1 | 2019 | 209 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 6489 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2019 | 401 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 3772 | 0.040 |
Why?
|
| Neutropenia | 1 | 2003 | 895 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2018 | 9146 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5751 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2008 | 2725 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3920 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 29786 | 0.040 |
Why?
|
| Carrier State | 1 | 2019 | 518 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2020 | 1730 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 2916 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2020 | 21746 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2003 | 1349 | 0.030 |
Why?
|
| Transaminases | 1 | 2015 | 199 | 0.030 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2014 | 9 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 265 | 0.030 |
Why?
|
| Orthomyxoviridae | 1 | 2015 | 156 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 683 | 0.030 |
Why?
|
| Time Factors | 3 | 2018 | 40075 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 15076 | 0.030 |
Why?
|
| Alaska | 1 | 2013 | 68 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 15540 | 0.030 |
Why?
|
| Disease Progression | 2 | 2022 | 13284 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 25043 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2014 | 175 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 320 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1915 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2015 | 497 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2013 | 719 | 0.030 |
Why?
|
| Publishing | 1 | 2020 | 833 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2013 | 224 | 0.030 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 16689 | 0.030 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2013 | 172 | 0.030 |
Why?
|
| Cell Line | 2 | 2019 | 15997 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 3588 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2018 | 1086 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2015 | 599 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2014 | 449 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 4751 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2007 | 8324 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2557 | 0.020 |
Why?
|
| DNA Primers | 2 | 2005 | 2892 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2014 | 772 | 0.020 |
Why?
|
| Proteins | 1 | 2005 | 6103 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2015 | 1200 | 0.020 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2014 | 428 | 0.020 |
Why?
|
| Microfluidics | 1 | 2015 | 662 | 0.020 |
Why?
|
| Environment | 1 | 2015 | 1124 | 0.020 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2013 | 571 | 0.020 |
Why?
|
| Temperature | 1 | 2015 | 2206 | 0.020 |
Why?
|
| Chemokines | 1 | 2013 | 970 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2022 | 63114 | 0.020 |
Why?
|
| Prevalence | 2 | 2015 | 15226 | 0.020 |
Why?
|
| Linear Models | 1 | 2018 | 5952 | 0.020 |
Why?
|
| Survivors | 1 | 1998 | 2291 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 2216 | 0.020 |
Why?
|
| RNA, Double-Stranded | 1 | 2009 | 290 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 1607 | 0.020 |
Why?
|
| Prognosis | 2 | 2022 | 29063 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2013 | 1539 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 3206 | 0.020 |
Why?
|
| Equipment Design | 1 | 2015 | 3582 | 0.020 |
Why?
|
| Replicon | 1 | 2006 | 34 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3701 | 0.020 |
Why?
|
| Recurrence | 1 | 2018 | 8340 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2014 | 1736 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 6473 | 0.020 |
Why?
|
| Vaccination | 1 | 2018 | 3278 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2007 | 601 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2013 | 13033 | 0.020 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2005 | 167 | 0.010 |
Why?
|
| Base Sequence | 2 | 2005 | 12797 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 19905 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 12959 | 0.010 |
Why?
|
| Computer Systems | 1 | 2004 | 483 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12245 | 0.010 |
Why?
|
| Developing Countries | 1 | 2014 | 2815 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 2988 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2006 | 1654 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 3778 | 0.010 |
Why?
|
| Public Health | 1 | 2014 | 2603 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13408 | 0.010 |
Why?
|
| Infant | 2 | 2019 | 35136 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2015 | 6256 | 0.010 |
Why?
|
| Gene Expression | 1 | 2014 | 7799 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2014 | 23403 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2015 | 10481 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 15519 | 0.010 |
Why?
|
| Cytokines | 1 | 2013 | 7322 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20129 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 5892 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 3420 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 6171 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 35421 | 0.010 |
Why?
|
| Mitochondria | 1 | 2006 | 3520 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 7913 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 7279 | 0.010 |
Why?
|